Seiji Miyahara

Seiji Miyahara is a Partner and Senior Investment Director at Taiho Ventures, where he leverages his Ph.D. background to lead strategic venture capital initiatives across the biotechnology sector. He directs significant capital toward emerging drug discovery technologies, notably participating in a major $40 million Series A extension for hC Bioscience in November 2022. Furthermore, Miyahara played a key role in the $50 million Series A financing round for Magnet Biomedicine, co-investing alongside prominent industry players such as ARCH Venture Partners. Through his senior leadership position at the corporate venture arm, he actively evaluates novel modalities and complex biological targets to support early-stage enterprises developing highly innovative therapeutic platforms. His current investment focus centers on advancing precision medicine, molecular glues, and tRNA-based therapeutics to effectively address severe and complex protein dysfunctions within the life sciences industry.